Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellSTU:OC9 -4.38%75 FCF Margin % is 17.87% as of Jun. 2026, which is 129% above its 10-year median of 7.80. GuruFocus rates STU:OC9 with a GF Score™ of 75/100 and a GF Value™ of €33.44 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Omnicell ranks better than 74.06% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Omnicell's Free Cash Flow for the
three
months ended in Jun. 2026 was €48 Mil. Omnicell's Revenue for the
three
months ended in Jun. 2026 was €271 Mil. Therefore, Omnicell's FCF Margin % for the quarter that ended in Jun. 2026 was 17.87%.
The historical rank and industry rank for Omnicell's FCF Margin % or its related term are showing as below:
STU:OC9'
s FCF Margin % Range Over the Past 10 Years
Min: -0.8 Med: 7.8 Max: 15.32
Current: 10.21
During the past 13 years, the highest FCF Margin % of Omnicell was 15.32%. The lowest was -0.80%. And the median was 7.80%.
STU:OC9's FCF Margin % is ranked better than 74.06% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 3.12
vs STU:OC9: 10.21
The historical data trend for Omnicell's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OC9 vs HTFL, TDOC, OMDA: FCF Margin % Comparison
For the Health Information Services subindustry, Omnicell's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Omnicell's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (STU:OC9) has a FCF Margin % of 17.87% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Omnicell and its competitors. This is 129% above median its historical median of 7.80. According to the industry distribution chart, Omnicell ranks #173 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 25.9%.
Is Omnicell's FCF Margin % too high?
Omnicell's current FCF Margin % of 17.87% is 129% above median its 10-year median of 7.80. The Healthcare Providers & Services industry median FCF Margin % is 3.12. Omnicell's value of 17.87% is 472.8% above this industry median. Based on the distribution chart, Omnicell ranks #173 out of 667 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Omnicell has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omnicell's FCF Margin % compare to HTFL and TDOC?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #173 out of 667 companies for FCF Margin %. This puts Omnicell in the upper half of its industry. The industry median FCF Margin % is 3.12. Omnicell's value of 17.87% is 472.8% above this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 3.12, Omnicell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.12, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current FCF Margin % of 17.87% is 472.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current FCF Margin % is 17.87%, which is 129% above median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Based on GuruFocus' analysis, Omnicell (STU:OC9) is currently considered Modestly Undervalued. The stock's GF Value™ is €33.44, compared to a current price of €30.60 — trading 8.5% below its estimated fair value. The current FCF Margin % is 17.87%, which is 129% above median its 10-year median of 7.80 and 472.8% above the Healthcare Providers & Services industry median of 3.12. Omnicell's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Omnicell (STU:OC9), the current FCF Margin % is 17.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (STU:OC9) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be undervalued.
The current stock price of €30.60 is trading 8.5% below its estimated GF Value™ of €33.44.
GuruFocus considers Omnicell to be Modestly Undervalued.
Key valuation signals for STU:OC9:
FCF Margin %: 17.87% (129% above median its 10-year median of 7.80)
GF Value™: €33.44 vs. price of €30.60 (8.5% below fair value)
Industry Position: 472.8% above the Healthcare Providers & Services median (#173 of 667)
No single metric tells the full story. See the STU:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
75GF Score
Get the complete analysis for STU:OC9
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OC9 has been successfully added to your 
